This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ehrenforth, S. Articles by Ganser, A. Search for Related Content PubMed PubMed Citation Articles by Ehrenforth, S. Articles by Ganser, A. Related Collections Risk Factors Coagulation and fibronolysis Genetics of cardiovascular disease

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:276-280.)
© 1999 American Heart Association, Inc.

Original Contributions

Study of the Prothrombin Gene 20201 GA Variant in FV:Q⁵⁰⁶ Carriers in Relationship to the Presence or Absence of Juvenile Venous Thromboembolism

S. Ehrenforth; M. von Depka Prondsinski; E. Aygören-Pürsün; U. Nowak-Göttl; I. Scharrer; A. Ganser

From the Department of Internal Medicine, University Hospital, Frankfurt am Main (S.E., E.A-P., I.S.); the Department of Internal Medicine, Medical School, Hannover (M. von D.P., A.G.); and the Department of Pediatrics, University Hospital, Münster (U.N-G.), Germany.

Correspondence to Dr S. Ehrenforth, Department of Internal Medicine I, HS 13A, J.W. Goethe University Hospital, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany. E-mail ehrenforth{at}em.uni-frankfurt.de

Abstract—The G20210A transition of the prothrombin gene has been identified as a common but probably mild hereditary risk factor for venous thromboembolism (VTE). However, the prothrombin gene variant might contribute to the penetrance of thromboembolic disease in many patients with other prothrombotic defects, such as the FV:R506Q mutation. In this investigation, the A20210 allele was found in 9 of 450 healthy controls (2%). Among 89 asymptomatic FV:Q⁵⁰⁶ carriers, 3 subjects were doubly affected (3.4%). In contrast, of 263 unrelated carriers of the FV:Q⁵⁰⁶ mutant with a history of juvenile VTE, 30 also had the prothrombin gene G20210A variant (11.4%), including 25 of 220 patients who were heterozygous (11.4%) and 5 of 43 homozygous (11.6%) for FV:Q⁵⁰⁶. Thus, the A20210 allele of the prothrombin gene is significantly overrepresented in symptomatic FV:Q⁵⁰⁶ carriers compared with healthy controls (P<0.0001) and asymptomatic relatives carrying the FV mutant (P=0.02). Persons homozygous for the 20210A allele were not found. A statistically significant increase in the prevalence of more unusual sites of venous thrombosis at clinical onset was found in doubly affected patients (9 of 30; 30%) compared with patients without the prothrombin gene variant (26 of 233; 11.1%) (P=0.004). First VTE occurred spontaneously in 53.3% of all doubly affected patients (16 of 30) and in 28.3% of all simply affected patients (66 of 233) (P=0.005). Among patients with VTE preceded by circumstantial risk factors, the A20210 allele was found in 7.7% (14 of 181). We conclude that the A20210 allele of the prothrombin gene is frequently coinherited in symptomatic FV:Q⁵⁰⁶ carriers and possibly influences age, site, and type of thrombotic onset manifestation in these patients.

Key Words: genes • variation (genetics) • prothrombin • factor V • mutation • thrombosis, venous

This article has been cited by other articles:

				C. J. Glueck and Ping Wang Ocular Vascular Thrombotic Events: A Diagnostic Window to Familial Thrombophilia (Compound Factor V Leiden and Prothrombin Gene Heterozygosity) and Thrombosis Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 12 - 18. [Abstract] [PDF]

				G. Young, M. Albisetti, M. Bonduel, L. Brandao, A. Chan, F. Friedrichs, N. A. Goldenberg, E. Grabowski, C. Heller, J. Journeycake, et al. Impact of Inherited Thrombophilia on Venous Thromboembolism in Children: A Systematic Review and Meta-Analysis of Observational Studies Circulation, September 23, 2008; 118(13): 1373 - 1382. [Abstract] [Full Text] [PDF]

				G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]

				U. Seligsohn and A. Lubetsky Genetic Susceptibility to Venous Thrombosis N. Engl. J. Med., April 19, 2001; 344(16): 1222 - 1231. [Full Text] [PDF]

				U. Nowak-Gottl, R. Junker, W. Kreuz, A. von Eckardstein, A. Kosch, N. Nohe, R. Schobess, and S. Ehrenforth Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors Blood, February 15, 2001; 97(4): 858 - 862. [Abstract] [Full Text] [PDF]

				M. D. Smirnov, O. Safa, N. L. Esmon, and C. T. Esmon Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin Blood, December 1, 1999; 94(11): 3839 - 3846. [Abstract] [Full Text] [PDF]

				R. Junker, H.-G. Koch, K. Auberger, N. Munchow, S. Ehrenforth, and U. Nowak-Gottl Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2568 - 2572. [Abstract] [Full Text] [PDF]

				G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]